Reynolds Seeks to Join Altria Lawsuit Over FDA PMTA Deadline Calculation

Executive summary

Three R.J. Reynolds entities have filed a motion to intervene in Altria’s ongoing lawsuit challenging the FDA’s 2021 PMTA final rule, specifically targeting the agency’s method for calculating the 180-day decision period. The companies argue that the FDA’s use of Acceptance and Filing reviews creates ambiguity and extends review timelines, undermining compliance certainty. This development reflects broader industry frustration with prolonged PMTA processing and its impact on market competition.

Regulatory risk: The FDA’s interpretation of when the 180-day clock starts remains legally contested, creating uncertainty for all PMTA applicants.

What happened

R.J. Reynolds Vapor Company, R.J. Reynolds Tobacco Company, and RJRT Holdings LLC have formally requested to join the lawsuit initiated by Altria subsidiaries Helix Innovations and NJOY. The suit challenges the FDA’s implementation of the 2021 PMTA final rule, particularly the agency’s practice of counting the 180-day review period from the date of an Acceptance or Filing review determination rather than from the submission of a complete application.

The companies assert that this approach effectively resets or delays the start of the 180-day deadline, allowing the FDA to extend review timelines beyond statutory expectations. They also contend that the current process enables unauthorized vaping products—often lacking proper regulatory scrutiny—to gain market share during extended review periods.

Why it matters

The dispute centers on a critical procedural point: when does the FDA’s 180-day decision obligation begin? Under the Tobacco Control Act, the FDA must make a determination within 180 days of receiving a complete PMTA submission. However, the agency has historically used Acceptance and Filing reviews as triggers for the clock, which can occur weeks or months after initial submission.

This interpretation has created significant legal and operational ambiguity. Companies argue that the law intends the clock to start upon receipt of a complete application, not after administrative milestones. If upheld, this could force the FDA to accelerate decisions and reduce backlogs, reshaping the entire PMTA landscape.

Market impact

Prolonged PMTA reviews have already distorted market dynamics. Authorized brands face delayed entry or renewal, while unregulated products—often sold through e-commerce platforms or third-party retailers—fill the gap. This undermines investment in compliant innovation and erodes consumer trust in regulated products.

Reynolds’ intervention underscores growing concern among major players about competitive imbalance. As more companies seek to enter or renew their PMTA status, the pressure to resolve timeline disputes intensifies. A favorable court ruling could trigger a wave of new applications and faster approvals, potentially increasing product availability and market transparency.

Regulatory impact

The outcome of this litigation could redefine how the FDA interprets its statutory obligations under the Tobacco Control Act. If courts side with the plaintiffs, the agency may be forced to revise its internal procedures, including how it defines “complete” submissions and when review clocks begin.

This would require systemic changes across the Center for Tobacco Products (CTP), affecting staffing, design, and public communication. It could also lead to increased judicial oversight of FDA actions, setting precedents for future challenges to other regulatory processes.

Who is affected

• Big tobacco manufacturers: Altria, R.J. Reynolds, and other large firms with active PMTA portfolios.
• Smaller vape startups: Those relying on timely PMTA decisions to launch or renew products.
• Regulatory compliance teams: Legal and operations staff managing PMTA submissions across the industry.
• Wholesale and retail distributors: Entities dependent on approved product availability for inventory planning.
• Consumers: Affected by product scarcity and inconsistent access to regulated alternatives.

Market impact: A shift toward faster PMTA decisions could level the playing field between authorized and unauthorized products.

Dawsen Take

This legal move marks a pivotal moment in the evolution of U.S. vaping regulation. By aligning with Altria’s challenge, R.J. Reynolds is signaling that procedural fairness and predictability are now as critical as substantive review outcomes. The case is less about individual product approval and more about establishing clear, enforceable rules for the entire PMTA system.

While the FDA has made progress reducing its backlog—reporting a 30% decrease in pending PMTAs since 2024—the legal framework remains contested. Courts may ultimately determine whether the agency’s current practices violate congressional intent. The stakes go beyond one company’s timeline; they touch the legitimacy of the entire regulatory regime.

What to watch

Key developments to monitor include:

• The court’s decision on Reynolds’ motion to intervene—expected within 60 days.
• Whether the judge will allow the case to proceed on the merits of the 180-day calculation issue.
• Any potential appeals or amicus briefs from trade associations or public health groups.
• Changes in FDA internal guidance following a possible adverse ruling.
• Impact on upcoming PMTA submissions, especially from smaller innovators.

For more daily vaping news, check out dawsenai.com.

Original source: 2FIRSTS | Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline